Business Context and Reporting Period
This Form 8-K Current Report was filed by Achieve Life Sciences, Inc. on January 6, 2025. The filing addresses Item 5.02 regarding the departure of a director and the appointment of new directors to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Director Departure: Dr. Vaughn Himes resigned from the Board of Directors effective immediately on January 6, 2025. The resignation was not due to any disagreement with the Company. Dr. Himes will continue to provide consulting services.
- Director Appointments: The Board appointed Nancy R. Phelan and Kristen B. Slaoui, Ph.D. as directors, effective January 6, 2025.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the incoming directors under the Non-Employee Director Compensation Program:
- Annual Retainer: Each incoming director receives a $40,000 annual retainer for the fiscal year ending December 31, 2025.
- Initial Stock Options: On January 13, 2025, each director was granted an option to purchase 47,250 shares of common stock. These options vest monthly over three years, subject to continued service.
- Annual Equity Compensation: Directors are entitled to customary annual equity compensation consisting of an option to purchase 31,500 shares, vesting in full on the earlier of the first anniversary of the grant or the date prior to the next annual meeting.
- Indemnification: Standard indemnification agreements have been entered into with the incoming directors.
Investor Verification Checklist
- Verify the impact of Dr. Himes' departure on ongoing consulting relationships and strategic direction.
- Review the qualifications and backgrounds of the new directors, Nancy R. Phelan and Kristen B. Slaoui, Ph.D.
- Monitor the dilution impact of the 47,250 shares granted to each new director and future annual grants.
- Confirm the vesting schedule and exercise price of the stock options granted on January 13, 2025.